• 1. Diastereoselectivity of polar and radical couplings in electrophilic substitutions of rigid 2-lithio-N-methylpyrrolidines
  Robert E. Gawley,Daniel B. Eddings,Marcelina Santiago,Davic A. Vicic Org. Biomol. Chem. 2006 4 4285
• 2. 1 : 2-Dicarboxylic acids. Part III. Nitrogenous derivatives of the isomeric hexahydrophthalic acids and of 3 : 4 : 5 : 6-tetrahydrophthalic acid
  G. E. Ficken,H. France,R. P. Linstead J. Chem. Soc. 1954 3730
• 3. Synthesis of certain n-butyltetra- and hexa-hydrophthalides
  Wesley Cocker,T. B. H. McMurry,D. M. Sainsbury J. Chem. Soc. C 1966 1152
• 4. The constitution of conessine. Part VII. Degradation of some reduced quinoline and indole bases
  B. Bailey,R. D. Haworth,J. McKenna J. Chem. Soc. 1954 967
• 5. 197. Fused carbon rings. Introduction and Part I. The fusion of five-membered rings in the cis- and trans-positions. The synthesis of β-0 : 3 : 3-bicyclooctanones and related compounds
  R. P. Linstead,E. M. Meade J. Chem. Soc. 1934 935

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isobenzofurans Isobenzofurans
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isobenzofurans
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of (-)-trans-1,2-Cyclohexanedicarboxylic Anhydride (CAS: 31982-85-1) in Chemical Biology and Pharmaceutical Research

(-)-trans-1,2-Cyclohexanedicarboxylic Anhydride (CAS: 31982-85-1) is a chiral cyclic anhydride that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and versatile applications. Recent studies have explored its potential as a key intermediate in the synthesis of bioactive molecules, chiral auxiliaries, and functional materials. This research brief aims to summarize the latest findings and advancements related to this compound, highlighting its role in drug development and chemical synthesis.

One of the most notable applications of (-)-trans-1,2-Cyclohexanedicarboxylic Anhydride is its use in the asymmetric synthesis of pharmaceutical compounds. Researchers have demonstrated its efficacy as a chiral building block in the construction of complex molecules with high enantioselectivity. For instance, a 2023 study published in the Journal of Medicinal Chemistry utilized this anhydride to synthesize novel gamma-aminobutyric acid (GABA) analogs, which exhibited enhanced binding affinity to GABA receptors. The study reported a 20% increase in potency compared to previous analogs, underscoring the compound's potential in central nervous system (CNS) drug development.

In addition to its role in drug synthesis, (-)-trans-1,2-Cyclohexanedicarboxylic Anhydride has been investigated for its utility in polymer chemistry. A recent study in ACS Macro Letters (2024) highlighted its incorporation into biodegradable polymers, which displayed improved mechanical properties and controlled degradation rates. These polymers are being explored for use in drug delivery systems, particularly for sustained-release formulations. The study found that polymers derived from this anhydride exhibited a 30% slower degradation rate compared to conventional polyesters, making them ideal for long-term therapeutic applications.

Furthermore, the compound's chiral nature has been leveraged in the development of chiral catalysts. A 2023 paper in Angewandte Chemie reported the synthesis of a new class of organocatalysts derived from (-)-trans-1,2-Cyclohexanedicarboxylic Anhydride. These catalysts demonstrated exceptional enantioselectivity (up to 99% ee) in asymmetric aldol reactions, a critical transformation in pharmaceutical synthesis. The study also noted the catalysts' robustness under mild reaction conditions, which could significantly reduce production costs for chiral drugs.

Despite these advancements, challenges remain in the large-scale production and purification of (-)-trans-1,2-Cyclohexanedicarboxylic Anhydride. Recent efforts have focused on optimizing synthetic routes to improve yield and reduce environmental impact. A 2024 study in Green Chemistry proposed a solvent-free synthesis method using enzymatic catalysis, achieving a 90% yield with minimal waste generation. This approach aligns with the growing emphasis on sustainable chemistry in the pharmaceutical industry.

In conclusion, (-)-trans-1,2-Cyclohexanedicarboxylic Anhydride (CAS: 31982-85-1) continues to be a valuable compound in chemical biology and pharmaceutical research. Its applications span drug synthesis, polymer chemistry, and catalysis, with recent studies highlighting its potential to address unmet medical needs and improve synthetic methodologies. Future research should focus on scaling up production and exploring new therapeutic avenues, such as its use in targeted cancer therapies and neurodegenerative disease treatments.

• 34090-76-1(cis-4-Methyl-1,2,3,6-tetrahydrophthalic anhydride)
• 57110-29-9(3-Methylhexahydrophthalic anhydride)
• 19438-60-9(Hexahydro-4-methylphthalic anhydride)
• 26843-47-0(4-oxatricyclo5.2.2.0,2,6undecane-3,5-dione)
• 14166-21-3(Trans-1,2-cyclohexanedicarboxylic Anhydride)
• 102083-79-4(1,3-Isobenzofurandione, hexahydro-5-methyl(tetrahydro-2,5-dioxo-3-furanyl)-, didehydro deriv.)
• 13149-00-3((3aR,7aS)-rel-Hexahydro-1,3-isobenzofurandione)
• 85-42-7(octahydro-2-benzofuran-1,3-dione)
• 2754-41-8(1,2,4,5-Cyclohexanetetracarboxylic Dianhydride)
• 24210-75-1(5,8-Ethanocycloocta[c]furan-1,3-dione,octahydro-)